{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:59:07Z","timestamp":1782842347691,"version":"3.54.5"},"reference-count":27,"publisher":"JMIR Publications Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Internet Res"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In view of repeated COVID-19 outbreaks in most countries, clinical trials will continue to be conducted under outbreak prevention and control measures for the next few years. It is very significant to explore an optimal clinical trial management model during the outbreak period to provide reference and insight for other clinical trial centers worldwide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to explore the management strategies used to minimize the impact of the COVID-19 epidemic on oncology clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We implemented a remote management model to maintain clinical trials conducted at Beijing Cancer Hospital, which realized remote project approval, remote initiation, remote visits, remote administration and remote monitoring to get through two COVID-19 outbreaks in the capital city from February to April and June to July 2020. The effectiveness of measures was evaluated as differences in rates of protocol compliance, participants lost to follow-up, participant withdrawal, disease progression, participant mortality, and detection of monitoring problems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the late of the first outbreak, modifications were made in trial processing, participant management and quality control, which allowed the hospital to ensure the smooth conduct of 572 trials, with a protocol compliance rate of 85.24% for 3718 participants across both outbreaks. No COVID-19 infections were recorded among participants or trial staff, and no major procedural errors occurred between February and July 2020. These measures led to significantly higher rates of protocol compliance and significantly lower rates of loss to follow-up or withdrawal after the second outbreak than after the first, without affecting rates of disease progression or mortality. The hospital provided trial sponsors with a remote monitoring system in a timely manner, and 3820 trial issues were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>When public health emergencies occur, an optimal clinical trial model combining on-site and remote management could guarantee the health care and treatment needs of clinical trial participants, in which remote management plays a key role.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2196\/26799","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T15:25:56Z","timestamp":1613489156000},"page":"e26799","source":"Crossref","is-referenced-by-count":7,"title":["Minimizing the Impact of the COVID-19 Epidemic on Oncology Clinical Trials: Retrospective Study of Beijing Cancer Hospital"],"prefix":"10.2196","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2152-0828","authenticated-orcid":false,"given":"Zhiying","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2706-8526","authenticated-orcid":false,"given":"Min","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8136-1630","authenticated-orcid":false,"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3078-1015","authenticated-orcid":false,"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"key":"ref1","unstructured":"WHO timeline for COVID-19 response. Webpage in ChineseWorld Health Organization2021-02-24https:\/\/www.who.int\/zh\/news-room\/detail\/29-06-2020-covidtimeline"},{"key":"ref2","unstructured":"WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020World Health Organization202003112020-04-16https:\/\/www.who.int\/dg\/speeches\/detail"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041383"},{"key":"ref4","unstructured":"Clinical perspective in the context of COVID-19 \u2014 digital health communities in China: interpretation of TIRS literature February (summary). Webpage in ChineseWeChat202002142021-02-24https:\/\/mp.weixin.qq.com\/s\/QxTqogyqJeGpvPROLFydtw"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.09.024"},{"issue":"7","key":"ref6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.46883\/ONC.2020.3407.0265","volume":"34","author":"Lara Gongoria, AB","year":"2020","journal-title":"Oncology (Williston Park)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00093-1"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004113"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000712"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30096-6"},{"key":"ref11","unstructured":"Announcement of the State Food and Drug Administration and the National Health Commission on issuing the quality management standards for drug clinical trials. Webpage in ChineseNational Medical Products Administration, Health Commission of the People's Republic of China202004272021-02-24http:\/\/www.nhc.gov.cn\/yzygj\/s7659\/202004\/1d5d7ea301f04adba4c4e47d2e92eb96.shtml"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-00889-6"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/2168479016647987"},{"key":"ref14","unstructured":"FDA guidance on conduct of clinical trials of medical products during the COVID-19 public health emergencyUS Food & Drug Administration2020032021-02-24https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-pandemic"},{"key":"ref15","unstructured":"BrennanSEMA offers guidance on conducting trials during the COVID-19 pandemicRegulatory Affairs Professionals Society202003202021-02-24https:\/\/www.raps.org\/news-and-articles\/news-articles\/2020\/3\/ema-offers-guidance-on-conducting-trials-during-th"},{"key":"ref16","unstructured":"Considerations to support clinical trial monitoring oversight during COVID-19Association of Clinical Research Organizations202003132021-02-24https:\/\/www.acrohealth.org\/wp-content\/uploads\/2020\/03\/ACRO-Statement-on-Monitoring-Oversight-FINAL-3.13.20.pdf"},{"key":"ref17","unstructured":"Guidelines for the management of drug clinical trials during COVID-19 outbreaks (trial). Webpage in ChineseNational Medical Products Administration, Health Commission of the People's Republic of China202007142021-02-24https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/qtggtg\/20200715110101939.html"},{"key":"ref18","unstructured":"A risk-based approach to monitoring of clinical investigations questions and answersUS Food & Drug Administration2019032021-02-24https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/risk-based-approach-monitoring-clinical-investigations-questions-and-answers"},{"key":"ref19","unstructured":"Reply to suggestions on supporting the construction of \"Internet + Education\" and \"Internet + Medical and Health\" demonstration zones. Webpage in ChineseNational Health Commission of the People's Republic of China202007152021-02-24http:\/\/www.nhc.gov.cn\/wjw\/jiany\/202007\/b2bc9bf348d54c869c25b8eb67c2038f.shtml"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2196\/19284"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0213"},{"key":"ref22","unstructured":"COVID-19 and clinical trials: the Medidata perspectiveMedidata202007152021-02-24https:\/\/www.medidata.com\/en\/insight\/covid-19-and-clinical-trials-the-medidata-perspective\/"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.04.003"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00080-6"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.06.018"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0824-5"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1159\/000493883"}],"container-title":["Journal of Medical Internet Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jmir.org\/2021\/3\/e26799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:37:57Z","timestamp":1782841077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmir.org\/2021\/3\/e26799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2196\/26799","relation":{"has-preprint":[{"id-type":"doi","id":"10.2196\/preprints.26799","asserted-by":"object"}]},"ISSN":["1438-8871"],"issn-type":[{"value":"1438-8871","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]}}}